<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epcoritamab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epcoritamab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Epcoritamab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141663" href="/d/html/141663.html" rel="external">see "Epcoritamab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58257685"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cytokine release syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving epcoritamab. Initiate treatment with the epcoritamab step-up dosing schedule to reduce the incidence and severity of CRS. Withhold epcoritamab until CRS resolves or permanently discontinue based on severity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Immune effector cell-associated neurotoxicity syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening and fatal reactions, can occur with epcoritamab. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold epcoritamab until ICANS resolves or permanently discontinue based on severity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58290908"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Epkinly</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F59025058"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Epkinly</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58257688"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-CD20;</li>
<li>
                        Antineoplastic Agent, Anti-CD3;</li>
<li>
                        Antineoplastic Agent, Bispecific T Cell Engager;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F58280345"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Ensure patients are well-hydrated prior to epcoritamab initiation. Avoid administering epcoritamab to patients with active infection. Should only be administered by a qualified provider with appropriate medical support to manage severe reactions (eg, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome). The manufacturer recommends hospitalization for 24 hours following administration of the cycle 1 day 15 dosage (48 mg).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedication: </i>Premedicate prior to each dose in cycle 1; if patient experienced grade 2 or 3 cytokine release syndrome (CRS) with the previous dose, administer premedication in cycle 2 and beyond until epcoritamab is tolerated without subsequent grade 2 or higher CRS. See "Epcoritamab Recommended Premedications" table below.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Prophylaxis:</i> Provide prophylaxis for <i>Pneumocystis jirovecii</i> pneumonia prior to initiating epcoritamab. Consider initiating herpes virus prophylaxis prior to initiating epcoritamab to prevent herpes zoster reactivation. Consider prophylactic granulocyte colony-stimulating factor administration as appropriate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48925eaf-0a5b-4db7-8ad8-85a7a9637b97">Diffuse large B-cell lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diffuse large B-cell lymphoma, relapsed or refractory: SUBQ: </b></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Epcoritamab Dosing Schedule<sup>a,b</sup> (28-day Treatment Cycles)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">Cycle number</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Day of treatment</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Epcoritamab dose<sup>b</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Continue until disease progression or unacceptable toxicity.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Manufacturer's labeling, Thieblemont 2023.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">Cycle 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.16 mg SUBQ (step up dose 1)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 8</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.8 mg SUBQ (step up dose 2)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 15</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mg SUBQ (first full dose)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 22</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mg SUBQ</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cycles 2 and 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Days 1, 8, 15, and 22</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mg SUBQ</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cycles 4 to 9</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Days 1 and 15</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mg SUBQ</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cycles 10 and beyond<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Day 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">48 mg SUBQ</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommendations for Restarting Epcoritamab After a Dosing Delay</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">Last dose administered</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Time since last dose</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Action for next epcoritamab dose(s)<sup>a</sup></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Administer premedications prior to epcoritamab dose and monitor appropriately.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cycle 1, day 1 (0.16 mg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;8 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Repeat 0.16 mg SUBQ, then administer 0.8 mg SUBQ the following week, followed by 2 weekly doses of 48 mg SUBQ. Then resume the planned dosage schedule beginning with day 1 of the subsequent cycle.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cycle 1, day 8 (0.8 mg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤14 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Administer 48 mg SUBQ, then resume the recommended dosage schedule.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;14 days</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Repeat 0.16 mg SUBQ, then administer 0.8 mg SUBQ the following week, followed by 2 weekly doses of 48 mg SUBQ. Then resume the planned dosage schedule beginning with day 1 of the subsequent cycle.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cycle 1, day 15 and beyond (48 mg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">≤6 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Administer 48 mg SUBQ, then resume the recommended dosage schedule.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;6 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Repeat 0.16 mg SUBQ, then administer 0.8 mg SUBQ the following week, followed by 2 weekly doses of 48 mg SUBQ. Then resume the planned dosage schedule beginning with day 1 of the subsequent cycle.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Epcoritamab Recommended Premedications</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">Cycle</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Patients requiring premedication</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Premedication</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Administration schedule</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Epcoritamab should be permanently discontinued if grade 4 CRS occurs.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>b</sup> CRS = cytokine release syndrome.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Cycle 1</p></td>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">All patients</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dexamethasone 15 mg oral or IV or prednisolone 100 mg oral or IV (or equivalent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to 120 minutes prior to each weekly epcoritamab dose <b>and</b> for 3 consecutive days following each weekly epcoritamab dose in cycle 1</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diphenhydramine 50 mg (or equivalent) orally or IV</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to 120 minutes prior to each weekly epcoritamab dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Acetaminophen 650 to 1,000 mg orally</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to 120 minutes prior to each weekly epcoritamab dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Cycle 2 and beyond</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Patients who experienced grade 2 or 3<sup>a</sup> CRS<sup>b</sup> with the previous dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dexamethasone 15 mg oral or IV or prednisolone 100 mg oral or IV (or equivalent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 to 120 minutes prior to the next epcoritamab dose after a grade 2 or 3<sup>a</sup> CRS event <b>and</b> for 3 consecutive days following the next epcoritamab dose until epcoritamab is administered and tolerated without subsequent ≥ grade 2 CRS.</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58280347"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Kidney function estimated using the Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to &lt;90 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant difference in epcoritamab pharmacokinetics was observed based on CrCl 30 to &lt;90 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (effects on epcoritamab pharmacokinetics are unknown).</p></div>
<div class="block doha drugH1Div" id="F58280348"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤ ULN with AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling; however, no clinically significant difference in epcoritamab pharmacokinetics was observed based on mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate or severe impairment (total bilirubin &gt;1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (effects on epcoritamab pharmacokinetics are unknown).</p></div>
<div class="block doo drugH1Div" id="F58280349"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>American</i>
<i> Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2</sup> experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F58280374"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Refer to "Dosing: Adult" for recommendations on restarting epcoritamab after dose delays.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytokine release syndrome:</b> If cytokine release syndrome (CRS) is suspected, interrupt epcoritamab until CRS resolves; manage according to the table below and per clinical practice guidelines. Supportive therapy for CRS may include intensive care for severe or life-threatening CRS. Identify CRS based on the clinical presentation. Evaluate for other causes (eg, fever, hypotension, hypoxia) and manage appropriately.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Epcoritamab-Related CRS Management<sup>d</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>CRS grade</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Presenting symptoms</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Fever may be masked by premedications; if clinical presentation is consistent with CRS, follow CRS management recommendations.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Refer to "Dosing: Adult" for recommendations for restarting epcoritamab after a dosing delay.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>If grade 2 or 3 CRS occurs with the second full epcoritamab dose (48 mg) or beyond, administer CRS premedications with each subsequent dose until an epcoritamab dose is administered without subsequent ≥ grade 2 CRS. Refer to "Dosing: Adult" for recommended premedications.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>d</sup> CRS = cytokine release syndrome; CPAP = continuous positive airway pressure; BiPAP = bilevel positive airway pressure.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup>, attributed to CRS.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab and manage per practice guidelines.</p>
<p style="text-indent:0em;text-align:left;">Ensure CRS symptoms are resolved prior to the next epcoritamab dose<sup>b</sup>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a </sup>with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension not requiring vasopressors</p>
<p style="text-indent:0em;text-align:left;">and/or</p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring low-flow oxygen (&lt;6 L/minute) via nasal cannula or blow-by.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab and manage per practice guidelines.</p>
<p style="text-indent:0em;text-align:left;">Ensure CRS symptoms are resolved prior to the next epcoritamab dose<sup>b</sup>.</p>
<p style="text-indent:0em;text-align:left;">Administer premedication<sup>c</sup> prior to the next epcoritamab dose.</p>
<p style="text-indent:0em;text-align:left;">For the next dose, monitor more frequently and consider hospitalization.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension requiring a vasopressor (with or without vasopressin)</p>
<p style="text-indent:0em;text-align:left;">and/or</p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring high-flow oxygen (≥6 L/minute) via nasal cannula, face mask, non-rebreather mask, or Venturi mask.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab and manage per practice guidelines, which may include intensive care.</p>
<p style="text-indent:0em;text-align:left;">Ensure CRS symptoms are resolved prior to the next epcoritamab dose<sup>b</sup>.</p>
<p style="text-indent:0em;text-align:left;">Administer premedication<sup>c</sup> prior to the next epcoritamab dose.</p>
<p style="text-indent:0em;text-align:left;">Hospitalize for the next epcoritamab dose.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">Grade 3, recurrent</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue epcoritamab.</p>
<p style="text-indent:0em;text-align:left;">Manage CRS per practice guidelines and provide supportive therapy, which may include intensive care.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Temperature ≥38°C (100.4°F)<sup>a</sup> with:</p>
<p style="text-indent:0em;text-align:left;">Hypotension requiring multiple vasopressors (excluding vasopressin)</p>
<p style="text-indent:0em;text-align:left;">and/or</p>
<p style="text-indent:0em;text-align:left;">Hypoxia requiring oxygen via positive pressure (eg, CPAP, BiPAP, intubation, mechanical ventilation).</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue epcoritamab.</p>
<p style="text-indent:0em;text-align:left;">Manage CRS per practice guidelines and provide supportive therapy, which may include intensive care.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune effector cell-associated neurotoxicity syndrome: </b>Monitor for signs/symptoms of immune effector cell-associated neurotoxicity syndrome (ICANS). Interrupt epcoritamab at the first sign of neurologic toxicity, including ICANS, and consider neurology evaluation. Rule out other causes of neurologic symptoms. Manage ICANS according to the table below and consider further management according to current practice guidelines.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Epcoritamab-Related ICANS Management<sup>e</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Grade </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Presenting symptoms<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Management is determined by the most severe event (not attributable to any other cause).</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) assessment:</p>
<ul>
<li>
<p style="text-indent:0em;">Orientation (oriented to year, month, city, hospital = 4 points)</p></li>
<li>
<p style="text-indent:0em;">Naming (name 3 objects, eg, point to clock, pen, button = 3 points)</p></li>
<li>
<p style="text-indent:0em;">Following commands (eg, “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point)</p></li>
<li>
<p style="text-indent:0em;">Writing (ability to write a standard sentence = 1 point)</p></li>
<li>
<p style="text-indent:0em;">Attention (count backwards from 100 by 10 = 1 point)</p></li>
<li>
<p style="text-indent:0em;">If unarousable and unable to perform ICE assessment (grade 4 ICANS = 0 points).</p></li></ul></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Not attributable to any other cause.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Refer to "Dosing: Adult" for recommendations for restarting epcoritamab after a dosing delay.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>e</sup> ICANS = immune effector cell-associated neurotoxicity syndrome.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ICE score 7 to 9<sup>b</sup>, <b>or</b></p>
<p style="text-indent:0em;text-align:left;">depressed level of consciousness<sup>c </sup>(awakens spontaneously)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab until ICANS resolves<sup>d</sup>. Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (eg, consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ICE score 3 to 6<sup>b</sup>, <b>or</b></p>
<p style="text-indent:0em;text-align:left;">depressed level of consciousness<sup>c</sup> (awakens to voice)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab until ICANS resolves<sup>d</sup>.</p>
<p style="text-indent:0em;text-align:left;">Administer dexamethasone 10 mg IV every 6 hours (or equivalent); continue dexamethasone until resolution to ≤ grade 1, then taper.</p>
<p style="text-indent:0em;text-align:left;">Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (including consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">ICE score 0 to 2<sup>b</sup>, <b>or </b></p>
<p style="text-indent:0em;text-align:left;">depressed level of consciousness<sup>c</sup> (awakens only to tactile stimulus), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">seizures<sup>c</sup> (either any clinical seizure, focal or generalized, that resolves rapidly, <b>or</b> nonconvulsive seizures on EEG that resolve with intervention), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">raised intracranial pressure (focal/local edema on neuroimaging<sup>c</sup>)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">First occurrence of grade 3 ICANS:</p>
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab until ICANS resolves<sup>d</sup>.</p>
<p style="text-indent:0em;text-align:left;">Administer dexamethasone 10 mg IV every 6 hours (or equivalent); continue dexamethasone until resolution to ≤ grade 1, then taper.</p>
<p style="text-indent:0em;text-align:left;">Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (including consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy as clinically appropriate (may include intensive care).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Recurrent grade 3 ICANS:</p>
<p style="text-indent:0em;text-align:left;">Permanently discontinue epcoritamab.</p>
<p style="text-indent:0em;text-align:left;">Administer dexamethasone 10 mg IV every 6 hours (or equivalent); continue dexamethasone until resolution to ≤ grade 1, then taper.</p>
<p style="text-indent:0em;text-align:left;">Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (including consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy as clinically appropriate (may include intensive care).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ICE score 0<sup>b</sup>, <b>or</b></p>
<p style="text-indent:0em;text-align:left;">depressed level of consciousness<sup>c</sup> (either unarousable or requires vigorous/repetitive tactile stimuli to arouse, or stupor or coma), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">seizures<sup>c</sup> (either life-threatening prolonged seizure &gt;5 minutes, or repetitive clinical or electrical seizures without return to baseline in between), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">motor findings<sup>c</sup> (deep focal motor weakness such as hemiparesis or paraparesis), <b>or</b></p>
<p style="text-indent:0em;text-align:left;">raised intracranial pressure/cerebral edema<sup>c</sup>, with signs/symptoms such as diffuse cerebral edema on neuroimaging, or decerebrate or decorticate posturing, or cranial nerve VI palsy, or papilledema, or Cushing triad</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue epcoritamab.</p>
<p style="text-indent:0em;text-align:left;">Administer dexamethasone 10 mg IV every 6 hours (or equivalent); continue dexamethasone until resolution to ≤ grade 1, then taper.</p>
<p style="text-indent:0em;text-align:left;">Alternatively, consider methylprednisolone 1,000 mg IV daily for ≥2 days.</p>
<p style="text-indent:0em;text-align:left;">Monitor neurologic symptoms and consider consultation with neurologist/other specialists for further evaluation and management (including consideration for initiating seizure prophylaxis with nonsedating, antiseizure medication).</p>
<p style="text-indent:0em;text-align:left;">Provide supportive therapy as clinically appropriate (may include intensive care).</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recom</b>
<b>mended Epcoritamab Dosage Modifications for Other Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Actions</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Refer to "Dosing: Adult" for recommendations for restarting epcoritamab after a dosing delay.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;500/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab until ANC is ≥500/mm<sup>3</sup>.<sup>a</sup> Consider prophylactic granulocyte colony-stimulating factor administration as appropriate.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab until platelets are ≥50,000/mm<sup>3</sup>.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Other cytopenias</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold or discontinue epcoritamab based on the severity.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infections</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grades 1 to 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab or consider permanently discontinuing based on severity. Manage infection appropriately and as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab in patients with active infection until infection resolves.<sup>a</sup></p>
<p style="text-indent:0em;text-align:left;">For grade 4 infection, consider permanently discontinuing epcoritamab.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 or higher</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold epcoritamab until adverse reaction resolves to grade 1 or baseline.<sup>a</sup></p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F58280346"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58265390"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum magnesium (31%), decreased serum phosphate (56%), decreased serum potassium (34%), decreased serum sodium (56%), increased serum potassium (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (23%), decreased appetite (12%), diarrhea (20%), nausea (20%; grades 3/4: 1%), vomiting (12%; grades 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (62%; grades 3/4: 12%), decreased neutrophils (50%; grades 3/4: 32%), decreased platelet count (48%; grades 3/4: 12%), decreased white blood cell count (53%; grades 3/4: 22%), lymphocytopenia (87%; grades 3/4: 77%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (45%), increased serum aspartate aminotransferase (48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Cytokine release syndrome (51%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Serious infection (15%; including opportunistic infection, pneumonia, sepsis, upper respiratory tract infection, and urinary track infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (29%), headache (13%), severe neurotoxicity (immune effector cell-associated neurotoxicity syndrome [ICANS]: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (28%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (24%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia, tumor flare, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion</p></div>
<div class="block coi drugH1Div" id="F58257691"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to epcoritamab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F58280303"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cytokine release syndrome: Epcoritamab may cause cytokine release syndrome (CRS); may be serious or life-threatening. CRS occurred in over half of patients who received epcoritamab at the recommended dose. Grades 1, 2, and 3 CRS were reported. Recurrent CRS was also reported. Most CRS events occurred during cycle 1, predominantly with the cycle 1, day 15 dose, although CRS also occurred with day 1, 8, and 22 doses. The median time to onset of CRS across all doses was 24 hours (range: up to 10 days) and the median time to CRS onset after the first full 48 mg dose was 21 hours (range: up to 7 days). CRS resolved in most patients and the median duration of CRS events was 2 days (range: 1 to 27 days). Signs/symptoms of CRS included pyrexia, chills, hypotension, hypoxia, dyspnea, and tachycardia. Concurrent neurological adverse reactions associated with CRS occurred in a small percentage of patients and included headache, confusion, tremors, dizziness, and ataxia. Patients who experience CRS (and/or other adverse reactions that impair consciousness) should be evaluated and advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cytopenias: Epcoritamab may cause serious or severe cytopenias, including neutropenia, anemia, and thrombocytopenia. Grade 3 and 4 cytopenias and neutropenic fever have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune effector cell-associated neurotoxicity syndrome:<b></b>Epcoritamab may cause immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening and fatal reactions. ICANS occurred in a small percentage of patients who received epcoritamab at the recommended dose. Grade 1 and 2 ICANS have been reported, along with one fatal ICANS case. Most ICANS events occurred during cycle 1 of epcoritamab treatment, with a median time to onset of ICANS of 16.5 days (range: 8 to 141 days) from the start of treatment in cycle 1. The median time to ICANS onset across all doses was 3 days (range: 1 to 13 days). The median duration of ICANS was 4 days (range: up to 8 days) with ICANS resolving with supportive care in most patients. Clinical manifestations of ICANS included (although not limited to) confusion, lethargy, tremor, dysgraphia, aphasia, and nonconvulsive status epilepticus. The onset of ICANS may be concurrent with CRS, following resolution of CRS, or in the absence of CRS. Patients who experience signs/symptoms of ICANS or any other adverse reactions impairing cognition or consciousness should be evaluated, including potential neurology evaluation, and patients at increased risk should be advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Epcoritamab may cause serious and fatal infections. Serious infections (≥ grade 3), including opportunistic infections have been reported with the recommended epcoritamab dose. The most common ≥ grade 3 infections were sepsis, COVID-19, urinary tract infection, pneumonia, and upper respiratory tract infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F58290909"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epkinly: Epcoritamab-bysp 4 mg/0.8 mL (0.8 mL); Epcoritamab-bysp 48 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F58290907"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58318468"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Epkinly Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/0.8 mL (per 0.8 mL): $1,545.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">48 mg/0.8 mL (per 0.8 mL): $18,544.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F59025059"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Epkinly: Epcoritamab-bysp 4 mg/0.8 mL (0.8 mL); Epcoritamab-bysp 48 mg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F58280298"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Epcoritamab is available through specialty distributors. Distribution information is available at https://www.epkinlyhcp.com/order.</p></div>
<div class="block adm drugH1Div" id="F58280379"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Inject required dose volume into the tissue of the lower part of the abdomen (preferred site) or the thigh. Rotate injection site from left to right (or vice versa), particularly during the weekly administrations (in cycles 1 to 3). Do not inject into tattoos or scars, or areas where the skin is red, bruised, tender, hard, or not intact.</p>
<p style="text-indent:-2em;margin-left:4em;">Epcoritamab should be prepared and administered by a health care provider. If refrigerated, allow epcoritamab solution to equilibrate to room temperature for no more than 1 hour before administration. Discard unused epcoritamab solution beyond the allowable storage time.</p></div>
<div class="block meg drugH1Div" id="F58339312"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Epkinly: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761324s000lbl.pdf%23page%3D26&amp;token=RGtyxXOD%2FQbflTgag541WPJ1QiqdcUOVavfoFx5eOL6yAcUgmiOC4%2FS1hOggzlVNHwygO1lYdkNtPf4UPDEDR%2BwPeNYHFPjNpsNHhwkTISZ7iDDXD6fUSy1VokfUj1gT&amp;TOPIC_ID=141559" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf#page=26</a></p></div>
<div class="block use drugH1Div" id="F58257690"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diffuse large B-cell lymphoma, relapsed or refractory:</b> Treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma in adults after 2 or more lines of systemic therapy.</p></div>
<div class="block mst drugH1Div" id="F58280295"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Epcoritamab may be confused with elotuzumab, mosunetuzumab, teclistamab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58280646"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58280643"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of anti-CD20 B-cell depleting therapy is reduced. Anti-CD20 B-Cell Depleting Therapies may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Administer COVID-19 vaccine 2 to 4 weeks prior to the next scheduled dose of anti-CD20 therapy, if used chronically for the treatment of autoimmune disease. Revaccinate 6 months after completion of anti-CD20 therapy if used over a limited period.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Epcoritamab may increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines 2 weeks prior to starting anti-CD20 B-cell depleting therapies. Vaccination of patients treated with these agents in the past 6 months is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Anti-CD20 B-Cell Depleting Therapies may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58280300"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 4 months after the last epcoritamab dose.</p></div>
<div class="block pri drugH1Div" id="F58280301"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Epcoritamab is a humanized bispecific antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Animal reproduction studies have not been conducted. Based on the mechanism of action, in utero exposure to epcoritamab may cause fetal harm. In addition, newborns exposed to epcoritamab in utero may develop B-cell lymphocytopenia.</p></div>
<div class="block brc drugH1Div" id="F58280302"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if epcoritamab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab is a humanized bispecific antibody (IgG<sub>1</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 4 months after the last epcoritamab dose.</p></div>
<div class="block mop drugH1Div" id="F58280382"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">CBC (throughout treatment). Verify pregnancy status prior to treatment (in patients who could become pregnant). Monitor for signs/symptoms of CRS (eg, pyrexia, chills, hypotension, hypoxia, dyspnea, tachycardia); at the first signs or symptoms, immediately evaluate patients for hospitalization. Monitor for neurological signs/symptoms of immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment; evaluate patient immediately at the first signs/symptoms of ICANS. Monitor hydration status. Monitor for signs/symptoms of infection (including opportunistic infections) prior to and during epcoritamab treatment.</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F58280320"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Epcoritamab is a bispecific T-cell engaging antibody that targets CD3 and CD20 (Thieblemont 2023). Epcoritamab binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. Epcoritamab activates T-cells resulting in the release of proinflammatory cytokines, and induces B-cell lysis.</p></div>
<div class="block phk drugH1Div" id="F58280321"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Circulating B cells decreased to undetectable levels (in patients who had detectable B cells at treatment initiation) following the approved recommended epcoritamab dose by cycle 1, day 15 (after the first full dose of 48 mg).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: B cell depletion was sustained throughout treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 25.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized into small peptides via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~22 days (after the end of cycle 3).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Following the first full (48 mg) dose in cycle 1: 4 days; following the end of cycle 3: 2.3 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: 0.53 L/day (after the end of cycle 3).</p></div>
<div class="block phksp drugH1Div" id="F58280329"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: In patients who received the recommended epcoritamab dose, cycle 1 median average concentration was 13% lower in a group of patients weighing 85 to 144 kg and 37% higher in a group of patients weighing 39 to 65 kg, compared to patients weighing 65 to &lt;85 kg.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Epkinly (epcoritamab) [prescribing information]. Plainsboro, NJ: Genmab US Inc; May 2023.</div>
</li>
<li>
<div class="reference">
                  Epkinly (epcoritamab) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021:39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36548927">
<a name="36548927"></a>Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large b-cell lymphoma: dose expansion in a phase I/II trial. <i>J Clin Oncol</i>. 2023;41(12):2238-2247. doi:10.1200/JCO.22.01725<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/epcoritamab-drug-information/abstract-text/36548927/pubmed" id="36548927" target="_blank">36548927</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141559 Version 25.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
